title: Prognostic Subgroups among Patients with Stage II Colon Cancer.
abstract: Colon cancer has traditionally been treated surgically. However, many cases of colon cancer are systemic at the time of diagnosis, and apparently curative surgery is followed at a later date by tumor recurrence as a consequence of circulating tumor cells before the surgery. Adjuvant medical therapies are designed to prevent recurrences after surgical resection. The current standard for clinical prognostication relies principally on pathological staging. In early-stage colon cancers (stages I and II), all the tumor is contained within the wall of the colon. Less than 10% of patients with stage I disease have a recurrence, and adjuvant chemotherapy is . . .
authors.affiliation: From the Center for Gastrointestinal Research, and the Center for Epigenetics, Cancer Prevention and Genomics, Baylor Research Institute, and the Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center - all in Dallas.
authors.forename: C Richard
authors.initials: CR
authors.lastname: Boland
authors.forename: Ajay
authors.initials: A
authors.lastname: Goel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D000071616:CDX2 Transcription Factor; D003110:Colonic Neoplasms / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D018398:Homeodomain Proteins / Q000378:metabolism*; D006801:Humans; D008297:Male
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000071616:CDX2 Transcription Factor; C491270:CDX2 protein, human; D018398:Homeodomain Proteins